In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program
In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program
The purpose of this study is to study whether percutaneous chronic total occlusion (CTO)
 revascularization, by the use of Percutaneous Coronary Intervention (PCI), stenting,
 guidewire, and catheter, improves a patient's quality of life and their left ventricular
 function, reduces angina severity, and improves long-term survival.
The purpose of this study is to study whether percutaneous chronic total occlusion (CTO)
 revascularization, by the use of Percutaneous Coronary Intervention (PCI), stenting,
 guidewire, and catheter, improves a patient's quality of life and their left ventricular
 function, reduces angina severity, and improves long-term survival. The study will consist of
 the two following groups:

 Retrospective patients This group will consist of consecutive patients that have already
 undergone CTO PCI by the PHI CTO team.

 -  The patients will be contacted by telephone for informed consent and will be asked how
 they are feeling and if they have seen any doctors for their heart conditions. The
 patient will also be asked if they are taking antiplatelet medicines as prescribed, and
 if there have been any changes in on their medicines.

 -  If more than 12 months have passed since the procedure, the patients will be queried
 regarding medical history

 -  If the patient cannot be contacted, then analysis of data will be limited to
 de-identified data collected from the chart, procedure angiogram, and the procedure
 report.

 Prospective patients This group will consist of patients in which the CTO procedure will be
 performed by the PHI CTO team.

 -  A clinical assessment will be performed before the stent procedure

 -  A blood sample will be taken for routine blood chemistry and hematology

 -  Medications will be prescribed to prevent blood clots

 -  Follow-up will occur 6 and 12 months post-procedure
Inclusion Criteria:

 1. The subject is > 18 years of age at the time of consent

 2. Subjects experiencing clinical symptoms considered suggestive of ischemic heart
 disease (eg, chest pain or discomfort or symptoms considered by the investigator to
 represent anginal equivalents) or having evidence of myocardial ischemia (eg, abnormal
 functional study) attributed to the CTO target vessel and scheduled for clinically
 indicated percutaneous CTO revascularization or are subjects with multi-vessel disease
 and/or Acute Coronary Syndrome (ACS) that are undergoing a staged CTO PCI procedure
 with the intent to achieve complete revascularization.

 3. Subject must have at least 1 target segment meeting non-acute total coronary occlusion
 as defined below. A CTO is any non-acute total coronary occlusion fulfilling the
 following angiographic characteristics and:

 1. High-grade native coronary stenosis

 2. Thrombolysis in Myocardial Infarction (TIMI) 0 or 1 antegrade flow

 3. Estimated in duration at least 3 months by clinical history and/or comparison
 with antecedent angiogram, functional study or electrocardiogram

 4. CTO segment may be de novo or previously treated via PCI

 4. Subject is eligible and consents to undergo or has undergone a PCI procedure

 5. Subject is an acceptable candidate for percutaneous transluminal coronary angioplasty
 (PTCA) and stenting.

 6. Subject is willing and able to provide informed consent as approved by local
 Institutional Review Board/Ethics Committee and to complete the protocol requirements
 for the study.

 7. Female subjects of child-bearing potential with a negative qualitative or quantitative
 pregnancy test in accordance to the Piedmont Hospital Policy.

 Exclusion Criteria:

 1. Any known allergy, hypersensitivity or contraindication to iodinated contrast that
 cannot be effectively managed medically

 2. Any known allergy, hypersensitivity or contraindication to clopidogrel bisulfate
 (Plavix®), prasugrel (Effient®) or ticagrelor (Brilinta®)-- for which alternative
 agents cannot be used-- or aspirin, heparin, nickel, stainless steel, zotarolimus, or
 everolimus

 3. Any contraindication to cardiac catheterization or to any of the standard concomitant
 therapies used during routine cardiac catheterization and PCI

 4. Subjects with any other pathology or indication which in the opinion of the
 investigator, might put the subject at risk, preclude follow-up, or in any way
 confound the results of the study

 5. Known previous medical condition yielding expected survival less than one year

 6. Subjects who are unable or unwilling to comply with the protocol or not expected to
 complete the study period, including its follow-up requirements

 7. Subjects with evidence of ongoing or active clinical instability including any of the
 following:

 1. Sustained systolic blood pressure < 100 mmHg (if different from baseline) or
 cardiogenic shock

 2. Acute pulmonary edema that has not been medically stabilized

 3. Suspected acute myocarditis, pericarditis, endocarditis, or cardiac tamponade

 4. Suspected dissecting aortic aneurysm

 8. Subjects with known clinically significant abnormal laboratory findings including:

 1. White Blood Cells (<1,000 WBC/mm3)

 2. Thrombocytopenia (<100,000 platelets/mm3)

 9. Subjects with history of bleeding diathesis or coagulapathy or refusal of blood
 transfusions

 10. Female subjects of child-bearing potential with a positive qualitative or quantitative
 pregnancy test or with a negative qualitative or quantitative pregnancy test who plan
 to become pregnant within 12 months of enrolling in the study